MARKET DEFINITION

Phosphodiesterase inhibitors prevent specific blood chemical processes. In addition to relaxing blood vessels, this also lowers inflammation. Although they have numerous additional applications linked to the heart and circulatory system, they are most famous for their usage in the treatment of erectile dysfunction. It improves circulation and lowers blood pressure by relaxing and widening blood vessels. They can thus be used to treat a variety of illnesses, such as issues with your skin, joints, heart, and lungs. This enzyme is a sort of molecule that makes chemical processes considerably quicker and simpler than they would otherwise be.

MARKET DYNAMICS

The main drivers of the industry's expansion include testosterone insufficiency, prostate cancer, obesity, hypertension, hyperlipidemia, and the use of specific medications that may cause erectile dysfunction. The growing use of PDE5 inhibitors, among other kinds, in the treatment of ED and pulmonary hypertension is contributing to the industry's expansion. However, throughout the course of the projected period, the diverse adverse effects connected with PDE inhibitors may restrain the expansion of the worldwide PDE inhibitors market. PDE inhibitors include side effects that include dyspepsia, headaches, and, to a lesser extent, myalgia, low back discomfort and flushing. The rise in the number of PDE inhibitors delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries is anticipated to create opportunities for market growth.

REPORT SCOPE

The report titled “Global Phosphodiesterase (PDE) Inhibitors Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Phosphodiesterase (PDE) Inhibitors market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Phosphodiesterase (PDE) Inhibitors market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Phosphodiesterase (PDE) Inhibitors Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

 MARKET SEGMENTATION

The Global Phosphodiesterase (PDE) Inhibitors Market is segmented based on type, medications, route of administration, application, end-users and region. Based on type, the market has been segmented into PDE-3, PDE-4 and PDE-5, whereas based on medications, the market comprises Anagrelide, Apremilast, Avanafil, Pentoxifylline and Others. Based on route of administration, the market has been segmented into Oral, Topical and Others, whereas, the application segmentation includes Heart and Circulatory Conditions, Inflammatory Diseases, Reproductive (Male) Disorders, Respiratory Conditions and Others. Based on end-users, the market has been segmented into Hospitals, Homecare, Specialty Clinics and Others.

COMPETITION LANDSCAPE

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Phosphodiesterase (PDE) Inhibitors market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Phosphodiesterase (PDE) Inhibitors market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Phosphodiesterase (PDE) Inhibitors market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Phosphodiesterase (PDE) Inhibitors industry in the past three years.

Key players in the Global Phosphodiesterase (PDE) Inhibitors Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

·         Bayer Inc

·         GlaxoSmithKline Plc

·         Vivus Inc.

·         Mylan N.V.

·         Novartis AG

·         Aurobindo Pharma

·         Abbvie Inc

·         Janssen Global Services, LLC

·         Bristol-Myers Squibb Company

·         Teva Pharmaceuticals Industries Ltd.

·         AstraZeneca

COVID-19 IMPACT ANALYSIS ON GLOBAL PHOSPHODIESTERASE (PDE) INHIBITORS MARKET

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

 

Report Attribute/Metric	Details
Market Size	In USD Million
CAGR	In % (2022-2028)
Base Year	2021
Forecast Period	2022 – 2028
Historical Data	2017 to 2021
Forecast Unit	Value (US$ Mn)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors and Trends
Geographies Covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key Players Analyzed	Bayer Inc, GlaxoSmithKline Plc, Vivus Inc., Mylan N.V., Novartis AG , Aurobindo Pharma, Abbvie Inc, Janssen Global Services, LLC, Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd, AstraZeneca
Customization & Pricing	Available on Request (10% Customization is Free)

 

RESEARCH PROGRAM DESIGN

 

KEY QUESTIONS ANSWERED

1.    What is the current size of the global Phosphodiesterase (PDE) Inhibitors market?

2.    What will be the growth rate of the market over the forecast period?

3.    Who are the key manufacturers/vendors in the Phosphodiesterase (PDE) Inhibitors market space?

4.    What are the major market opportunities and market risks faced by the market?

5.    What is the impact of COVID-19 on the market?

6.    What are the revenue, sales, and price analysis of the top manufacturers in this market?

7.    What are the key outcomes of Porter's five forces model?

8.    Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:

·         The report offers comprehensive data on the Phosphodiesterase (PDE) Inhibitors market elaborating on the current state and future growth prospects both globally and regionally

·         It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth

·         The report offers deep-dive insights into each market segment and critical factors responsible for its growth

·         The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position

·         The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions

·         Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope

·         The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

 

Chapter 1.  Executive Summary

1.1.   Market Outlook

1.2.   Market Segment Outlook

1.3.   Geography Outlook

1.4.   Absolute $ Opportunity

Chapter 2.  Research Methodology

2.1.   Research Approach

2.2.   Scope, Definition, and Assumptions

2.3.   Data Sources

2.3.1. Secondary Sources

2.3.1.1.         Preliminary Data Mining

2.3.2. Primary Sources

2.3.2.1.         Statistical Model

2.3.2.2.         Data Triangulation

2.3.2.3.         Research Objective

Chapter 3.  Market Outlook

3.1.   Introduction

3.2.   Key Trends

3.2.1. Type Trends

3.2.2. Medications Trends

3.2.3. Route of Administration Trends

3.2.4. Application Trends

3.2.5. End-Users Trends

3.3.   Market Dynamics

3.3.1. Market Drivers

3.3.1.1.         Impact Analysis of Market Drivers

3.3.2. Market Restraints

3.3.2.1.         Impact Analysis of Market Restraints

3.3.3. Market Opportunities

3.3.3.1.         Impact Analysis of Market Opportunities

3.3.4. Market Challenges

3.3.4.1.         Impact Analysis of Market Challenges

3.4.   Porter’s Five Forces’ Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of New Entrant

3.4.4. Threat of Substitutes

3.4.5. Competitive Rivalry

3.5.   Value Chain Analysis: Global Phosphodiesterase (PDE) Inhibitors Market

3.6.   COVID-19 Impact Assessment in Phosphodiesterase (PDE) Inhibitors Market

3.6.1. Impact Assessment on Global Phosphodiesterase (PDE) Inhibitors Market

3.6.2. Market Trends and Opportunities in the Covid-19 Landscape

Chapter 4.  Global Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

4.1.   Global Phosphodiesterase (PDE) Inhibitors Market Share, By Type, 2017 - 2028 (USD Million)

4.1.1. PDE-3

4.1.2. PDE-4

4.1.3. PDE-5

Chapter 5.  Global Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

5.1.   Global Phosphodiesterase (PDE) Inhibitors Market Share, By Medications, 2017 - 2028 (USD Million)

5.1.1. Anagrelide

5.1.2. Apremilast

5.1.3. Avanafil

5.1.4. Pentoxifylline

5.1.5. Others     

Chapter 6.  Global Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

6.1.   Global Phosphodiesterase (PDE) Inhibitors Market Share, By Route of Administration, 2017 - 2028 (USD Million)

6.1.1. Oral

6.1.2. Topical

6.1.3. Others

Chapter 7.  Global Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

7.1.   Global Phosphodiesterase (PDE) Inhibitors Market Share, By Application, 2017 - 2028 (USD Million)

7.1.1. Heart and Circulatory Conditions

7.1.2. Inflammatory Diseases

7.1.3. Reproductive (Male) Disorders

7.1.4. Respiratory Conditions

7.1.5. Others

Chapter 8.  Global Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

8.1.   Global Phosphodiesterase (PDE) Inhibitors Market Share, By End-Users, 2017 - 2028 (USD Million)

8.1.1. Hospitals

8.1.2. Homecare

8.1.3. Specialty Clinics

8.1.4. Others

Chapter 9.  Global Phosphodiesterase (PDE) Inhibitors Market Overview, By Geography, 2017 - 2028 (USD Million)

9.1.   Global Phosphodiesterase (PDE) Inhibitors Market Share, By Geography, 2017 - 2028 (USD Million)

9.1.1. Market Size and Projections, by Countries, 2017 - 2028 (USD Million)

9.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)

Chapter 10.      North America Phosphodiesterase (PDE) Inhibitors Market Overview, By Countries, 2017 - 2028 (USD Million)

10.1.  North America Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

10.1.1.   Market size and projections, 2017 - 2028 (USD Million)

10.1.2.   North America Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

10.1.3.   North America Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

10.1.4.   North America Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.1.5.   North America Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

10.1.6.   North America Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

10.2.  North America Phosphodiesterase (PDE) Inhibitors Market Overview, By Countries, 2017 - 2028 (USD Million)

10.2.1.   U.S. Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

10.2.1.1.       U.S. Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

10.2.1.2.       U.S. Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

10.2.1.3.       U.S. Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.2.1.4.       U.S. Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

10.2.1.5.       U.S. Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

10.2.2.   Canada Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

10.2.2.1.       Canada Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

10.2.2.2.       Canada Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

10.2.2.3.       Canada Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.2.2.4.       Canada Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

10.2.2.5.       Canada Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

10.2.3.   Mexico Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

10.2.3.1.       Mexico Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

10.2.3.2.       Mexico Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

10.2.3.3.       Mexico Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.2.3.4.       Mexico Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

10.2.3.5.       Mexico Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

Chapter 11.      Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By Countries, 2017 - 2028 (USD Million)

11.1.  Europe Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

11.1.1.   Market size and projections, 2017 - 2028 (USD Million)

11.1.2.   Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

11.1.3.   Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

11.1.4.   Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.1.5.   Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

11.1.6.   Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

11.2.  Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By Countries, 2017 - 2028 (USD Million)

11.2.1.   Germany Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

11.2.1.1.       Germany Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

11.2.1.2.       Germany Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

11.2.1.3.       Germany Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.2.1.4.       Germany Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.1.5.       Germany Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

11.2.2.   France Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

11.2.2.1.       France Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

11.2.2.2.       France Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

11.2.2.3.       France Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.2.2.4.       France Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.2.5.       France Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

11.2.3.   UK Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

11.2.3.1.       UK Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

11.2.3.2.       UK Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

11.2.3.3.       UK Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.2.3.4.       UK Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.3.5.       UK Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

11.2.4.   Italy Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

11.2.4.1.       Italy Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

11.2.4.2.       Italy Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

11.2.4.3.       Italy Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.2.4.4.       Italy Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.4.5.       Italy Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

11.2.5.   Spain Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

11.2.5.1.       Spain Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

11.2.5.2.       Spain Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

11.2.5.3.       Spain Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.2.5.4.       Spain Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.5.5.       Spain Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

11.2.6.   NORDIC Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

11.2.6.1.       NORDIC Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

11.2.6.2.       NORDIC Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

11.2.6.3.       NORDIC Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.2.6.4.       NORDIC Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.6.5.       NORDIC Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

11.2.7.   Russia and CIS Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

11.2.7.1.       Russia and CIS Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

11.2.7.2.       Russia and CIS Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

11.2.7.3.       Russia and CIS Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.2.7.4.       Russia and CIS Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.7.5.       Russia and CIS Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

11.2.8.   Rest of Europe Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

11.2.8.1.       Rest of Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

11.2.8.2.       Rest of Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

11.2.8.3.       Rest of Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.2.8.4.       Rest of Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.8.5.       Rest of Europe Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

Chapter 12.      Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By Countries, 2017 - 2028 (USD Million)

12.1.  Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

12.1.1.   Market size and projections, 2017 - 2028 (USD Million)

12.1.2.   Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

12.1.3.   Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

12.1.4.   Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.1.5.   Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

12.1.6.   Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

12.2.  Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By Countries, 2017 - 2028 (USD Million)

12.2.1.   India Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

12.2.1.1.       India Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

12.2.1.2.       India Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

12.2.1.3.       India Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.2.1.4.       India Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.1.5.       India Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

12.2.2.   China Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

12.2.2.1.       China Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

12.2.2.2.       China Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

12.2.2.3.       China Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.2.2.4.       China Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.2.5.       China Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

12.2.3.   Japan Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

12.2.3.1.       Japan Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

12.2.3.2.       Japan Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

12.2.3.3.       Japan Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.2.3.4.       Japan Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.3.5.       Japan Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

12.2.4.   ASEAN Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

12.2.4.1.       ASEAN Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

12.2.4.2.       ASEAN Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

12.2.4.3.       ASEAN Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.2.4.4.       ASEAN Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.4.5.       ASEAN Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

12.2.5.   South Korea Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

12.2.5.1.       South Korea Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

12.2.5.2.       South Korea Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

12.2.5.3.       South Korea Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.2.5.4.       South Korea Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.5.5.       South Korea Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

12.2.6.   Australia Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

12.2.6.1.       Australia Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

12.2.6.2.       Australia Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

12.2.6.3.       Australia Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.2.6.4.       Australia Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.6.5.       Australia Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

12.2.7.   Rest of Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

12.2.7.1.       Rest of Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

12.2.7.2.       Rest of Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

12.2.7.3.       Rest of Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.2.7.4.       Rest of Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.7.5.       Rest of Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

Chapter 13.      South America Phosphodiesterase (PDE) Inhibitors Market Overview, By Countries, 2017 - 2028 (USD Million)

13.1.  South America Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

13.1.1.   Market size and projections, 2017 - 2028 (USD Million)

13.1.2.   South America Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

13.1.3.   South America Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

13.1.4.   South America Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

13.1.5.   South America Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

13.1.6.   South America Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

13.2.  South America Phosphodiesterase (PDE) Inhibitors Market Overview, By Countries, 2017 - 2028 (USD Million)

13.2.1.   Brazil Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

13.2.1.1.       Brazil Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

13.2.1.2.       Brazil Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

13.2.1.3.       Brazil Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

13.2.1.4.       Brazil Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

13.2.1.5.       Brazil Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

13.2.2.   Argentina Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

13.2.2.1.       Argentina Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

13.2.2.2.       Argentina Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

13.2.2.3.       Argentina Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

13.2.2.4.       Argentina Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

13.2.2.5.       Argentina Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

13.2.3.   Rest of South America Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

13.2.3.1.       Rest of South America Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

13.2.3.2.       Rest of South America Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

13.2.3.3.       Rest of South America Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

13.2.3.4.       Rest of South America Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

13.2.3.5.       Rest of South America Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

Chapter 14.      Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Countries, 2017 - 2028 (USD Million)

14.1.  Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

14.1.1.   Market size and projections, 2017 - 2028 (USD Million)

14.1.2.   Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

14.1.3.   Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

14.1.4.   Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

14.1.5.   Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

14.1.6.   Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

14.2.  Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Countries, 2017 - 2028 (USD Million)

14.2.1.   GCC Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

14.2.1.1.       GCC Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

14.2.1.2.       GCC Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

14.2.1.3.       GCC Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

14.2.1.4.       GCC Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

14.2.1.5.       GCC Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

14.2.2.   South Africa Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

14.2.2.1.       South Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

14.2.2.2.       South Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

14.2.2.3.       South Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

14.2.2.4.       South Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

14.2.2.5.       South Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

14.2.3.   Rest of Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, 2017 - 2028 (USD Million)

14.2.3.1.       Rest of Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Type, 2017 - 2028 (USD Million)

14.2.3.2.       Rest of Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Medications, 2017 - 2028 (USD Million)

14.2.3.3.       Rest of Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

14.2.3.4.       Rest of Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By Application, 2017 - 2028 (USD Million)

14.2.3.5.       Rest of Middle East & Africa Phosphodiesterase (PDE) Inhibitors Market Overview, By End-Users, 2017 - 2028 (USD Million)

Chapter 15.      Competitive Landscape

15.1.  Competitive Environment, 2021

15.2.  Strategic Framework

15.2.1.   Partnership/Collaborations/Agreement

15.2.2.   Expansion

15.2.3.   Mergers & Acquisitions

15.2.4.   New Product Development

Chapter 16.      Key Vendor Analysis

16.1.              Bayer Inc

16.1.1.       Business Overview

16.1.2.       Product Benchmarking

16.1.3.       Financial Data

16.1.4.       Strategic Overview

16.1.5.       Key Developments

16.1.6.       SWOT Analysis

16.2.              GlaxoSmithKline Plc

16.2.1.       Business Overview

16.2.2.       Product Benchmarking

16.2.3.       Financial Data

16.2.4.       Strategic Overview

16.2.5.       Key Developments

16.2.6.       SWOT Analysis

16.3.              Vivus Inc.

16.3.1.       Business Overview

16.3.2.       Product Benchmarking

16.3.3.       Financial Data

16.3.4.       Strategic Overview

16.3.5.       Key Developments

16.3.6.       SWOT Analysis

16.4.              Mylan N.V.

16.4.1.       Business Overview

16.4.2.       Product Benchmarking

16.4.3.       Financial Data

16.4.4.       Strategic Overview

16.4.5.       Key Developments

16.4.6.       SWOT Analysis

16.5.              Novartis AG

16.5.1.       Business Overview

16.5.2.       Product Benchmarking

16.5.3.       Financial Data

16.5.4.       Strategic Overview

16.5.5.       Key Developments

16.5.6.       SWOT Analysis

16.6.              Aurobindo Pharma

16.6.1.       Business Overview

16.6.2.       Product Benchmarking

16.6.3.       Financial Data

16.6.4.       Strategic Overview

16.6.5.       Key Developments

16.6.6.       SWOT Analysis

16.7.              Abbvie Inc

16.7.1.       Business Overview

16.7.2.       Product Benchmarking

16.7.3.       Financial Data

16.7.4.       Strategic Overview

16.7.5.       Key Developments

16.7.6.       SWOT Analysis

16.8.              Janssen Global Services, LLC

16.8.1.       Business Overview

16.8.2.       Product Benchmarking

16.8.3.       Financial Data

16.8.4.       Strategic Overview

16.8.5.       Key Developments

16.8.6.       SWOT Analysis

16.9.              Bristol-Myers Squibb Company

16.9.1.       Business Overview

16.9.2.       Product Benchmarking

16.9.3.       Financial Data

16.9.4.       Strategic Overview

16.9.5.       Key Developments

16.9.6.       SWOT Analysis

16.10.            Teva Pharmaceuticals Industries Ltd.

16.10.1.    Business Overview

16.10.2.    Product Benchmarking

16.10.3.    Financial Data

16.10.4.    Strategic Overview

16.10.5.    Key Developments

16.10.6.    SWOT Analysis

16.11.            AstraZeneca

16.11.1.    Business Overview

16.11.2.    Product Benchmarking

16.11.3.    Financial Data

16.11.4.    Strategic Overview

16.11.5.    Key Developments

16.11.6.    SWOT Analysis

Chapter 17.   Future Outlook of the Market